| Literature DB >> 33328883 |
Pedro M Martins1,2, Susanna Navarro3, Alexandra Silva1, Maria F Pinto1, Zsuzsa Sárkány1, Francisco Figueiredo1,2,4, Pedro José Barbosa Pereira1, Francisca Pinheiro3, Zuzana Bednarikova5, Michał Burdukiewicz6, Oxana V Galzitskaya7,8, Zuzana Gazova5, Cláudio M Gomes9, Annalisa Pastore10, Louise C Serpell11, Rostislav Skrabana12,13, Vytautas Smirnovas14, Mantas Ziaunys14, Daniel E Otzen15, Salvador Ventura3, Sandra Macedo-Ribeiro1.
Abstract
Reports on phase separation and amyloid formation for multiple proteins and aggregation-prone peptides are recurrently used to explore the molecular mechanisms associated with several human diseases. The information conveyed by these reports can be used directly in translational investigation, e.g., for the design of better drug screening strategies, or be compiled in databases for benchmarking novel aggregation-predicting algorithms. Given that minute protocol variations determine different outcomes of protein aggregation assays, there is a strong urge for standardized descriptions of the different types of aggregates and the detailed methods used in their production. In an attempt to address this need, we assembled the Minimum Information Required for Reproducible Aggregation Experiments (MIRRAGGE) guidelines, considering first-principles and the established literature on protein self-assembly and aggregation. This consensus information aims to cover the major and subtle determinants of experimental reproducibility while avoiding excessive technical details that are of limited practical interest for non-specialized users. The MIRRAGGE table (template available in Supplementary Information) is useful as a guide for the design of new studies and as a checklist during submission of experimental reports for publication. Full disclosure of relevant information also enables other researchers to reproduce results correctly and facilitates systematic data deposition into curated databases.Entities:
Keywords: amyloid; peptide; phase separation; protein; reproducible data
Year: 2020 PMID: 33328883 PMCID: PMC7729192 DOI: 10.3389/fnmol.2020.582488
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
FIGURE 1Amyloid and non-amyloid aggregates. (A) Amyloids have the characteristic fibrillar appearance illustrated in this transmission electron microscopy (TEM) image of negatively stained fibrils from a peptide derived from the SH3 domain of PI3-kinase (SH3-PI3K) (Ventura et al., 2004). The bar corresponds to 200 nm. (B) The ordered β-sheet structure of amyloid fibrils produces the cross-β X-ray diffraction pattern here exemplified for fibrils of a peptide derived from Mot3 yeast prion (Sant’Anna et al., 2016; Fernandez et al., 2017). The blue and red arrows indicate typical reflections at 4.7 and 10.2 Å, respectively. (C) Thioflavin-S (Th-S) is an histological dye that shows fluorescence in presence of amyloid fibrils (example of SH3-PI3K fibrils stained with Th-S) (Ventura et al., 2004). The bar corresponds to 20 μm. (D) Folded and misfolded monomers are in dynamic equilibrium with soluble oligomers and may coexist in solution with different condensates, such as dense liquids and gels, amyloid fibrils and their protofibrillar precursors, crystals and amorphous solids. For simplicity, the more complex cases of fibril polymorphism, multiprotein assemblies or nucleic acid-protein assemblies are not shown, and amyloid fibrils are represented as composed of four protofilament units. (B) Adapted from (Sant’Anna et al., 2016). All copyright permissions have been secured by the authors.
FIGURE 2Ontological map of protein aggregation. Phase equilibria (solid outlines) are established between the liquid phase (green circle), the dense liquid phase (orange circle) and the solid phase (blue circles). The different species (represented as in Figure 1D) may undergo structural transitions (dashed lines) that originate distinct species within the same stable phase (different shades of color). Visual examples of aggregation pathways are provided, comprising many (arrow 1), some (arrow 2) and no (arrow 3) intermediate states. Off-pathway aggregation occurring in parallel with amyloid fibrillation is represented by a bifurcation (arrow 2′). The outcome of phase separation (black dots) is contingent on concentration, temperature, pH, ionic strength, amino acid sequence, etc., but also on the initial state of the protein, as it determines the point in the green region from where the experiments depart (white dots).
Glossary of terms used in protein aggregation phenomena.
| Amyloid fibril | Insoluble, protease resistant aggregate with characteristic (i) fibrillar electron microscopic appearance, (ii) X-ray fiber diffraction pattern and (iii) histological staining reactions, including Th-T fluorescence and green birefringence in the presence of Congo red. |
| Amyloidosis | Any disease associated with the formation of amyloid deposits, i.e., deposits that have amyloid fibrils as main constituent. |
| Condensate | The denser phase formed upon phase separation. |
| Embryo | A metastable cluster formed as the result of random molecular collisions; embryos will tend to disintegrate if smaller than the critical nucleus size. |
| Liquid demixing | Separation of a solution into two coexisting liquid phases (compare with phase separation); also known as “liquid-liquid demixing.” |
| Mature amyloid fibril | A long, fully stable amyloid fibril consisting of intertwined protofilament units producing a wound structure that is resistant to 2% (w/v) sodium dodecyl sulfate (SDS) treatment. |
| Nucleation | The stochastic process by which nuclei are formed; primary nucleation occurs in the homogeneous bulk solution; secondary nucleation occurs on the surface of an already existing aggregate; heterogeneous nucleation occurs on the surface of a foreign substance. |
| Nucleus | A cluster formed as the result of random molecular collisions and with the ability to elongate into a fibril (compare with embryo). |
| Off-pathway oligomer | Stable oligomer that coexists with amyloid fibrils but is not an amyloid percursor; off-pathway oligomerization and amyloid fibrillation are competitive processes. |
| Oligomer | Multimeric species lacking the morphology and properties of amyloid fibrils. |
| On-pathway oligomer | A precursor of amyloid fibrils; the addition of pre-formed on-pathway oligomers accelerates the formation of amyloid fibrils without affecting the total amyloid conversion. |
| Phase separation | The formation of a new region with uniform density and composition; it can occur instantaneously by spinodal decomposition, or via the energy-activated process of nucleation. |
| Protofibril | Beaded chain with ∼5 nm diameter and <150 nm length that matures into amyloid fibrils. |
| Protofilament | Subunit of amyloid fibrils; smaller protofilaments with ∼1 nm diameter entwine to form larger protofilament units with 2.5–3.5 nm diameter. |
| Seed | Preformed amyloid particle able to accelerate the assembly of amyloid fibrils. |
Experimental details that should be reported for protein aggregation assays.
| Reported parameter | Information that should be reported | |
| Sample stock | Description of protein source – commercial (supplier and reference), recombinant (including expression and purification), or other (e.g., extracted from tissue); description of how the protein or peptide stock was preserved (lyophilized or stored in solution); if stored in solution indicate storage buffer, sample concentration, storage temperature, freezing/thawing conditions, as well as material and supplier of vials used for sample storage. | |
| Indicate the methods (SDS-PAGE, HPLC, etc.) used to determine sample purity, as well as those used to determine the exact concentration of the stock sample in the assay. The purity of the sample stock as evaluated by SDS-PAGE should be indicated and higher than 95%. Indicate whether the sample was tested for the presence of “invisible” components such as nucleic acids. | ||
| Indicate the final concentration of the sample in the assay. | ||
| Mention if the protein/peptide stocks were pre-treated, filtered or centrifuged; these procedures are recommended to remove pre-aggregated forms. | ||
| Indicate the composition, concentrations and pH value of the buffer or solvent stock. | ||
| The final volume of the sample, as well as the volume of the tube/well in which the aggregation assay is performed should be reported since interfaces (liquid-solid and liquid-air) influence protein aggregation. The method used to prevent sample evaporation should also be mentioned when using small sample volumes. | ||
| List ALL components that could be found in the aggregation assay (even those that may exist in minute amounts). For example, if an aggregation modulator is dissolved in DMSO, it is important that all samples (including control) contain the same final concentration of DMSO. | ||
| Report the type of material and geometry of the vial or microplate well (binding versus non-binding surface, bottom versus top-reading, square versus round bottom, etc.) used in the assay. Include information on the microplate/vial material, including supplier and reference code. | ||
| Report the assay temperature. In particular, mention if samples/buffer are preincubated at the assay temperature: fluorescence drifts may be observed at the beginning of the experiment resulting from temperature shifts. | ||
| Indicate whether an orbital shaker, a thermomixer or magnetic stirring was used (describing shape, size and material of stirrers), the type of shaking (orbital, linear, etc.) and speed. If applicable, indicate if beads were included (material, size, number of beads). Measurement cycles and the pre-shaking agitation procedures should be clearly specified. | ||
| The total duration of the aggregation reaction should be reported. | ||
| Indicate the device make and model, control software, and general settings used (e.g., filter bandpass and bandwidth/monochromator settings). | ||
| Provide the exact amount of reporter (if used) employed for measurement and any pre-treatment of the sample. | ||
| Indicate the software (including version) used for image and data analysis and specify the equation applied for fitting kinetic data obtained from aggregation assays. |
FIGURE 3Aggregation of human ataxin-3 (UniProt accession code: P54252-2). (A) Schematic representation of the structural organization of ataxin-3, with the N-terminal globular Josephin domain (JD) and the flexible C-terminal tail encompassing the ubiquitin-interacting motifs (UIMs) and the polyQ tract containing 13 glutamine residues (13Q); (B) Representative graph of human ataxin-3 aggregation at 37°C monitored by Th-T fluorescence. (C) TEM image of ataxin-3 protofibrils at the end of the aggregation assay (∼60 h).